Quick Answer
HALOZYME THERAPEUTICS, INC. reported Revenue (ASC 606) of $1.40 billion for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.40B | +37.6% |
| 2024 | $1.02B | +22.4% |
| 2023 | $829.25M | +25.6% |
| 2022 | $660.12M | +48.9% |
| 2021 | $443.31M | +65.7% |
| 2020 | $267.59M | +36.5% |
| 2019 | $195.99M | +29.1% |
| 2018 | $151.86M | -52.0% |
| 2017 | $316.61M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $354.26M | +22.1% | +8.8% |
| June 30, 2025 | $325.72M | +40.8% | +23.0% |
| March 31, 2025 | $264.86M | +35.2% | -8.7% |
| September 30, 2024 | $290.08M | +34.3% | +25.4% |
| June 30, 2024 | $231.35M | +4.7% | +18.1% |
| March 31, 2024 | $195.88M | +20.8% | -9.3% |
| September 30, 2023 | $216.03M | +3.4% | -2.3% |
| June 30, 2023 | $221.04M | +45.1% | +36.3% |
- HALOZYME THERAPEUTICS, INC. showed an increase of +37.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, HALOZYME THERAPEUTICS, INC.’s revenue (asc 606) has grown by 341.1% (from $316.61 million to $1.40 billion).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: